⚗️ On Lithium — Prescribed or Low-Dose

What this panel can settle, and by what logic

Nine markers, because lithium acts on three separate organs by three separate mechanisms and a normal result in one says nothing about the other two Vantyghem 2023.

1. The blood level is part of taking the drug rather than an optional extra. The gap between an effective and a toxic concentration is narrow, and monitoring it is built into every modern review of the drug Gitlin 2024Ferensztajn-Rochowiak 2023.
2. TSH (Thyroid-Stimulating Hormone) with Free T4 (Thyroxine) and Thyroid Antibodies (TPO + TgAb) covers the commonest endocrine consequence. Lithium concentrates in the thyroid and inhibits hormone release, and thyroid disorders in long-term lithium users have been quantified in a historical cohort Joseph 2023. Pre-existing thyroid antibodies raise the risk, which makes measuring them once worth more than measuring TSH twice.
3. Parathyroid Hormone & Calcium catches the parathyroid effect, which is the one nobody is monitored for. Lithium acts on the calcium-sensing receptor, raising parathyroid hormone and calcium together in a pattern that resembles primary hyperparathyroidism; a cohort study measured hyperparathyroidism and hypercalcemia alongside kidney outcomes in long-term users Boivin 2023, and an expert management algorithm exists for it Kovacs 2022. The pair is essential, because a raised PTH with a normal calcium is a recognized and easily missed stage Shaker 2023.
4. Urinalysis, Routine is the early kidney warning and it costs ten dollars. Lithium reduces the collecting duct's response to antidiuretic hormone, so concentrating ability falls long before filtration does. A dilute urine with a low specific gravity in somebody drinking normally is that change, years ahead of anything the Cystatin C with eGFR would show Boivin 2023.
5. The Complete Blood Count (CBC) with Differential is here to prevent an investigation. Lithium raises the white cell count as a benign expected effect, and it gets worked up when nobody knew to expect it Ferensztajn-Rochowiak 2023.

What it cannot settle, and what would

It cannot tell you whether your dose is right, and nothing on this page is a reason to change or stop a psychiatric medication. That judgment is clinical, uses how you are as well as the number, and belongs to whoever prescribes it. Abrupt discontinuation of lithium carries its own well-described risk Gitlin 2024.

It cannot detect early toxicity from the level alone. Tremor, unsteadiness, confusion, vomiting or diarrhea on lithium are urgent regardless of what the last result said, and chronic toxicity can occur at concentrations inside the usual range Ferensztajn-Rochowiak 2023.

It cannot predict an interaction before it happens. Anti-inflammatories, thiazide diuretics and ACE inhibitors all raise lithium concentrations, and dehydration does the same Ferensztajn-Rochowiak 2023. A level drawn before any of those started does not describe the situation after.

And it cannot distinguish lithium-associated hyperparathyroidism from the primary kind. They look the same biochemically; the distinction rests on the timeline, imaging and sometimes on what happens when the drug changes, which is a specialist decision Kovacs 2022.

Draw conditions that decide whether the money is wasted

The level is only meaningful as a trough, and everything else on the panel is ordinary.

1. Draw the Lithium 12 hours after the last dose. A sample taken four hours after a tablet is substantially higher and cannot be compared with a previous or a future one Gitlin 2024.
2. Not within a week of starting, stopping or changing the dose, and not within a week of starting an anti-inflammatory, a diuretic or an ACE inhibitor Ferensztajn-Rochowiak 2023.
3. Fast 9 to 12 hours and draw in the morning for the Parathyroid Hormone & Calcium pair, which follows a daily rhythm.
4. Come normally hydrated, but do not water-load before the Urinalysis, Routine. Drinking a liter in the waiting room manufactures the dilute sample this panel is looking for.
5. If you take low-dose orotate rather than prescription lithium, expect the level to be below the reporting limit. That is the useful result: a measurable level on a supplement dose means the dose is not what the label says.

How you would know it answered your question, and what each pattern means next

Four patterns, each with the interval at which it should be rechecked.

• Trough Lithium inside your prescriber's range, normal TSH (Thyroid-Stimulating Hormone), normal Parathyroid Hormone & Calcium, concentrated urine: unchanged, and the standard is periodic repetition rather than discharge Gitlin 2024.
• Rising TSH (Thyroid-Stimulating Hormone) with a normal Free T4 (Thyroxine), especially with positive Thyroid Antibodies (TPO + TgAb): compensated hypothyroidism, usually managed by adding thyroid hormone rather than by stopping lithium Joseph 2023. Recheck TSH at 8 to 12 weeks after any change.
• Raised PTH with a raised or high-normal calcium: the parathyroid effect. This belongs with an endocrinologist and has a published management algorithm Kovacs 2022; a raised PTH with a still-normal calcium is the earlier stage of the same thing Shaker 2023.
• Persistently dilute Urinalysis, Routine, or a Cystatin C with eGFR filtration rate falling across two draws: the kidney signal, and the one that changes long-term planning Boivin 2023.

Sources read for these sections

• Boivin E, et al. Long-term lithium therapy and risk of chronic kidney disease, hyperparathyroidism and hypercalcemia: a cohort study. International Journal of Bipolar Disorders 2023 · PMID 36709463
• Kovacs Z, et al. Lithium induced hypercalcemia: an expert opinion and management algorithm. International Journal of Bipolar Disorders 2022 · PMID 36547749
• Gitlin M, et al. Lithium: current state of the art and future directions. International Journal of Bipolar Disorders 2024 · PMID 39609318
• Joseph B, et al. Long-Term Lithium Therapy and Thyroid Disorders in Bipolar Disorder: A Historical Cohort Study. Brain Sciences 2023 · PMID 36672114
• Ferensztajn-Rochowiak E, et al. Long-Term Lithium Therapy: Side Effects and Interactions. Pharmaceuticals (Basel) 2023 · PMID 36678571
• Vantyghem MC, et al. Iatrogenic endocrine complications of lithium therapy. Annales d'Endocrinologie 2023 · PMID 36963758
• Shaker JL, Wermers RA. The Eucalcemic Patient With Elevated Parathyroid Hormone Levels. Journal of the Endocrine Society 2023 · PMID 36793479